|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000136457 |
Summary for CHAD |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000136457 | Gene symbol | CHAD |
| Gene name | chondroadherin | |
| HGNC | 1909 | |
| Entrez ID | 1101 | |
| Gene type | protein_coding | |
| Synonyms | CHAD|SLRR4A | |
| UniProtAcc | O15335 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for CHAD |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CHAD | 8.20e+01 | 1.22e+00 | 5.32e-01 | 2.29e+00 | 2.23e-02 | 4.71e-02 | BLCA |
| CHAD | 2.33e+02 | -3.23e+00 | 6.67e-01 | -4.84e+00 | 1.27e-06 | 2.93e-05 | ESCA |
| CHAD | 5.69e+02 | -3.68e+00 | 6.77e-01 | -5.43e+00 | 5.54e-08 | 5.31e-07 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CHAD | 6.37e+01 | -3.17e+00 | 3.19e-01 | -9.95e+00 | 2.41e-23 | 6.09e-22 | COAD |
| CHAD | 2.31e+03 | 1.50e+00 | 2.19e-01 | 6.85e+00 | 7.25e-12 | 1.70e-11 | BRCA |
Top |
Sex-biased somatic mutation for CHAD |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for CHAD |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg15506894 | chr17:50468444 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 5.15e-01 | 3.89e-01 | 1.99e+00 | 4.69e-02 | 4.88e-02 | 1.26e-01 |
| SARC | cg25792518 | chr17:50468589 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 5.11e-01 | 3.77e-01 | 3.15e+00 | 1.64e-03 | 5.10e-03 | 1.34e-01 |
| MESO | cg22627841 | chr17:50468897 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 2.28e-01 | 3.65e-01 | -2.13e+00 | 3.29e-02 | 4.55e-02 | -1.37e-01 |
| MESO | cg15880760 | chr17:50468929 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 2.29e-01 | 3.41e-01 | -2.08e+00 | 3.78e-02 | 4.71e-02 | -1.12e-01 |
| MESO | cg19046826 | chr17:50468936 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 2.04e-01 | 3.26e-01 | -2.04e+00 | 4.11e-02 | 4.79e-02 | -1.22e-01 |
| MESO | cg05180443 | chr17:50469193 | CGI:chr17:50468209-50469539 | promoter | 1.47e-01 | 2.53e-01 | -2.18e+00 | 2.93e-02 | 4.40e-02 | -1.06e-01 |
| MESO | cg06958829 | chr17:50468757 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 3.60e-01 | 4.76e-01 | -2.30e+00 | 2.12e-02 | 3.95e-02 | -1.16e-01 |
| MESO | cg17890928 | chr17:50468832 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 2.09e-01 | 3.21e-01 | -2.38e+00 | 1.71e-02 | 3.65e-02 | -1.12e-01 |
| ACC | cg22627841 | chr17:50468897 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 4.09e-01 | 5.54e-01 | -2.25e+00 | 2.45e-02 | 3.84e-02 | -1.45e-01 |
| CHOL | cg25792518 | chr17:50468589 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 8.40e-01 | 7.21e-01 | 2.10e+00 | 3.56e-02 | 4.34e-02 | 1.19e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| THCA | cg09576319 | chr17:50467363 | CGI:chr17:50468209-50469539 | promoter,gene body | 7.73e-01 | 6.57e-01 | 3.62e+00 | 2.95e-04 | 1.29e-03 | 1.16e-01 |
| COAD | cg25792518 | chr17:50468589 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 8.51e-01 | 7.48e-01 | 3.18e+00 | 1.47e-03 | 3.07e-03 | 1.03e-01 |
| COAD | cg19961043 | chr17:50469070 | CGI:chr17:50468209-50469539 | promoter | 6.28e-01 | 5.20e-01 | 3.69e+00 | 2.21e-04 | 6.61e-04 | 1.08e-01 |
| COAD | cg05180443 | chr17:50469193 | CGI:chr17:50468209-50469539 | promoter | 5.75e-01 | 4.42e-01 | 3.64e+00 | 2.73e-04 | 7.84e-04 | 1.33e-01 |
| COAD | cg06958829 | chr17:50468757 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 7.35e-01 | 6.29e-01 | 3.64e+00 | 2.73e-04 | 7.84e-04 | 1.06e-01 |
| COAD | cg06818777 | chr17:50469259 | CGI:chr17:50468209-50469539 | promoter | 5.79e-01 | 4.66e-01 | 3.74e+00 | 1.87e-04 | 5.77e-04 | 1.13e-01 |
| BLCA | cg15506894 | chr17:50468444 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 8.70e-01 | 7.28e-01 | 3.91e+00 | 9.24e-05 | 3.78e-04 | 1.41e-01 |
| ESCA | cg25792518 | chr17:50468589 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 6.84e-01 | 4.52e-01 | 2.52e+00 | 1.17e-02 | 3.69e-02 | 2.32e-01 |
| ESCA | cg15880760 | chr17:50468929 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 4.65e-01 | 3.53e-01 | 2.05e+00 | 4.09e-02 | 4.70e-02 | 1.12e-01 |
| ESCA | cg19046826 | chr17:50468936 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 4.63e-01 | 3.43e-01 | 2.14e+00 | 3.20e-02 | 4.44e-02 | 1.20e-01 |
| ESCA | cg10421979 | chr17:50468960 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 4.66e-01 | 3.25e-01 | 2.16e+00 | 3.05e-02 | 4.39e-02 | 1.41e-01 |
| ESCA | cg19961043 | chr17:50469070 | CGI:chr17:50468209-50469539 | promoter | 4.12e-01 | 2.02e-01 | 2.48e+00 | 1.31e-02 | 3.74e-02 | 2.10e-01 |
| ESCA | cg13764778 | chr17:50469142 | CGI:chr17:50468209-50469539 | promoter | 5.00e-01 | 2.70e-01 | 2.14e+00 | 3.20e-02 | 4.44e-02 | 2.29e-01 |
| ESCA | cg05180443 | chr17:50469193 | CGI:chr17:50468209-50469539 | promoter | 4.30e-01 | 1.65e-01 | 2.87e+00 | 4.12e-03 | 3.39e-02 | 2.65e-01 |
| ESCA | cg17890928 | chr17:50468832 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 4.80e-01 | 2.92e-01 | 2.28e+00 | 2.24e-02 | 4.12e-02 | 1.88e-01 |
| ESCA | cg06818777 | chr17:50469259 | CGI:chr17:50468209-50469539 | promoter | 4.71e-01 | 2.85e-01 | 2.97e+00 | 2.99e-03 | 3.38e-02 | 1.86e-01 |
| CHOL | cg25792518 | chr17:50468589 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 7.21e-01 | 3.81e-01 | 2.88e+00 | 4.04e-03 | 1.47e-02 | 3.40e-01 |
| CHOL | cg15506894 | chr17:50468444 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 8.70e-01 | 6.93e-01 | 2.73e+00 | 6.38e-03 | 1.82e-02 | 1.77e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg22627841 | chr17:50468897 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 2.12e-01 | 6.96e-02 | 3.38e+00 | 7.17e-04 | 9.59e-04 | 1.42e-01 |
| BRCA | cg15880760 | chr17:50468929 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 2.26e-01 | 1.04e-01 | 4.65e+00 | 3.40e-06 | 5.98e-06 | 1.21e-01 |
| BRCA | cg19046826 | chr17:50468936 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 1.96e-01 | 6.44e-02 | 3.77e+00 | 1.66e-04 | 2.41e-04 | 1.32e-01 |
| BRCA | cg10421979 | chr17:50468960 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 1.87e-01 | 5.87e-02 | 2.59e+00 | 9.61e-03 | 1.09e-02 | 1.28e-01 |
| BRCA | cg19961043 | chr17:50469070 | CGI:chr17:50468209-50469539 | promoter | 1.68e-01 | 3.45e-02 | 3.22e+00 | 1.28e-03 | 1.65e-03 | 1.34e-01 |
| BRCA | cg13764778 | chr17:50469142 | CGI:chr17:50468209-50469539 | promoter | 2.32e-01 | 1.02e-01 | 2.30e+00 | 2.15e-02 | 2.30e-02 | 1.31e-01 |
| BRCA | cg05180443 | chr17:50469193 | CGI:chr17:50468209-50469539 | promoter | 2.14e-01 | 6.71e-02 | 2.98e+00 | 2.86e-03 | 3.52e-03 | 1.47e-01 |
| BRCA | cg09576319 | chr17:50467363 | CGI:chr17:50468209-50469539 | promoter,gene body | 8.02e-01 | 9.07e-01 | -7.63e+00 | 2.37e-14 | 8.21e-14 | -1.05e-01 |
| BRCA | cg15506894 | chr17:50468444 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 5.15e-01 | 6.32e-01 | -6.04e+00 | 1.55e-09 | 3.70e-09 | -1.17e-01 |
| BRCA | cg06958829 | chr17:50468757 | CGI:chr17:50468209-50469539 | promoter,exon,CDS,gene body | 3.00e-01 | 1.86e-01 | 2.76e+00 | 5.72e-03 | 6.71e-03 | 1.13e-01 |
| BRCA | cg17890928 | chr17:50468832 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 2.15e-01 | 9.13e-02 | 4.51e+00 | 6.43e-06 | 1.10e-05 | 1.24e-01 |
| LIHC | cg15880760 | chr17:50468929 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 6.07e-01 | 5.02e-01 | 4.85e+00 | 1.24e-06 | 1.54e-05 | 1.05e-01 |
| LIHC | cg19046826 | chr17:50468936 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 6.18e-01 | 5.06e-01 | 4.75e+00 | 2.05e-06 | 2.19e-05 | 1.12e-01 |
| LIHC | cg10421979 | chr17:50468960 | CGI:chr17:50468209-50469539 | UTR,promoter,exon,gene body | 6.23e-01 | 5.12e-01 | 4.55e+00 | 5.25e-06 | 4.30e-05 | 1.11e-01 |
| LIHC | cg06818777 | chr17:50469259 | CGI:chr17:50468209-50469539 | promoter | 6.04e-01 | 4.99e-01 | 4.00e+00 | 6.44e-05 | 2.76e-04 | 1.05e-01 |
Top |
Exon skipping events with PSI in TCGA for CHAD |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for CHAD |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for CHAD |
| TFs related to CHAD. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| UVM | ZNF235 | CHAD | 4.44e+00 | 9.83e-01 | 1.53e+00 | 1.88e-04 | Male-biased |
| UVM | ZNF287 | CHAD | 4.46e+00 | 9.83e-01 | 1.74e+00 | 3.27e-04 | Male-biased |
| UVM | ZNF879 | CHAD | 4.41e+00 | 9.82e-01 | 1.31e+00 | 1.07e-04 | Male-biased |
| CHAD related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for CHAD |
| RBPs related to ES in CHAD. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CHAD related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12602493 | chr17:41061195:T:C | - | 0.0406797742219033 | 0.00954295653503451 | LUAD | Female-baised eQTL |
| rs76044633 | chr17:41061453:A:G | - | 0.0406797742219033 | 0.00954295653503451 | LUAD | Female-baised eQTL |
| rs76228597 | chr17:41062054:T:C | - | 0.0406797742219033 | 0.00954295653503451 | LUAD | Female-baised eQTL |
| rs74421445 | chr17:41062061:A:G | - | 0.0406797742219033 | 0.00954295653503451 | LUAD | Female-baised eQTL |
| rs77525318 | chr17:41062120:C:T | - | 0.0406797742219033 | 0.00954295653503451 | LUAD | Female-baised eQTL |
| rs75476906 | chr17:41062365:T:A | - | 0.0406797742219033 | 0.00954295653503451 | LUAD | Female-baised eQTL |
| rs113631986 | chr17:41062447:A:G | - | 0.0406797742219033 | 0.00954295653503451 | LUAD | Female-baised eQTL |
| rs75363163 | chr17:41062553:G:A | - | 0.0406797742219033 | 0.00954295653503451 | LUAD | Female-baised eQTL |
| rs111513610 | chr17:41062776:G:T | - | 0.0406797742219033 | 0.00954295653503451 | LUAD | Female-baised eQTL |
| rs113397060 | chr17:41059833:C:T | - | 0.0398640525208876 | 0.0114369927243728 | LUAD | Female-baised eQTL |
| rs2004600 | chr17:57742429:G:A | - | 0.0363739233066381 | 0.0133389792997069 | LUAD | Female-baised eQTL |
| rs12453194 | chr17:41053203:C:T | - | 0.039120830901858 | 0.0133720596117702 | LUAD | Female-baised eQTL |
| rs2958950 | chr17:54853060:A:G | - | 0.0341465651471235 | 0.0255885242034597 | LUAD | Female-baised eQTL |
| rs2958946 | chr17:54858322:A:G | - | 0.0331947162141515 | 0.0311580143230572 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs72628303 | chr17:42481967:G:A | - | 0.116728041064068 | 0.0427615579566847 | SARC | Male-baised eQTL |
| rs75848506 | chr17:58189912:G:A | - | 0.144541652460527 | 0.0462713616914402 | LIHC | Male-baised eQTL |
| rs1317254 | chr17:43577832:T:C | - | 0.0501606756880251 | 0.0378407886159187 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000136457 |
| CpG Site: cg06958829 | |
| Position to Gene: gene,exon,CDS,promoter | |
| Male Effect: - | |
| Female Effect: -0.10021724326041 | |
 | Gene ID: ENSG00000136457 |
| CpG Site: cg25792518 | |
| Position to Gene: gene,exon,CDS,promoter | |
| Male Effect: - | |
| Female Effect: -0.0944703831545115 | |
 | Gene ID: ENSG00000136457 |
| CpG Site: cg06958829 | |
| Position to Gene: gene,exon,CDS,promoter | |
| Male Effect: - | |
| Female Effect: -0.0729614357846166 | |
 | Gene ID: ENSG00000136457 |
| CpG Site: cg15506894 | |
| Position to Gene: gene,exon,CDS,promoter | |
| Male Effect: - | |
| Female Effect: -0.228253176484858 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg06958829 | chr17:50468757 | gene,exon,CDS,promoter | -0.10021724326041 | 6.90436072943305e-10 | -0.42458347714302397 | 1.3926534198116438e-12 | LUAD |
| cg25792518 | chr17:50468589 | gene,exon,CDS,promoter | -0.0944703831545115 | 3.7875709237743e-10 | -0.5156004342829713 | 1.5165040065628074e-13 | SKCM |
| cg06958829 | chr17:50468757 | gene,exon,CDS,promoter | -0.0729614357846166 | 1.42493893050272e-07 | -0.45524020647942404 | 1.5280233432494978e-10 | SKCM |
| cg15506894 | chr17:50468444 | gene,exon,CDS,promoter | -0.228253176484858 | 4.0409903505943e-05 | -0.3874706473100015 | 8.39153066717708e-08 | SKCM |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of CHAD |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
